Insider Cluster (3 insiders) ·Filed May 26, 2026

BBIO

BridgeBio Pharma, Inc.
BEARISH
Impact 5/10
Horizonweeks Processed4mo ago
Insider cluster: 3 insiders, $1.2M total
Actionable Insight ▼ Bearish

The cluster of C-suite insider sales, while small in absolute terms, is amplified by cross-filing context suggesting material corporate events may be pending. Monitor for upcoming earnings, partnership agreements, or equity offerings that could explain the timing. The CEO and CFO both selling in the same window is unusual and warrants close attention.

DirectionBearish
Confidencemedium
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
BBIO ▲ +24.83% at T+60d
SHORT call ✗ call lost -24.83% · α vs SPY -22.95% · entry $66.44 → $82.94
Entry anchored
May 26, 2026
via day open
T+1d
+3.03%
call -3.03% · α -2.47%
$68.45
settled 4mo ago
T+5d
-1.44%
call +1.44% · α +1.91%
$65.48
settled 4mo ago
T+20d
+4.89%
call -4.89% · α -6.79%
$69.69
settled 3mo ago
T+60d
+24.83%
call -24.83% · α -22.95%
$82.94
settled 6w ago

Price Chart

Loading chart...

Executive Summary

Three BridgeBio insiders, including the CEO and President/CFO, sold a total of $1.24M in open-market sales over a 7-day window. While the dollar amount is modest relative to the $13.5B market cap (0.009%), the cluster includes the top two C-suite executives and is amplified by cross-filing context suggesting proximity to earnings, agreements, or offerings.

Key Financial Metrics

Direction
selling
Total Value
$1.2M
Insiders
3

Key Facts

  • Three insiders sold a total of $1.24M in open-market sales from May 14-21, 2026.
  • CEO Kumar Neil sold 2,256 shares at $67.57 for $152K.
  • President and CFO Thomas Trimarchi sold 10,500 shares at $64.82 for $678K.
  • Director Randal W. Scott sold 6,200 shares at $66.69 for $413K.
  • Total sales represent 0.009% of BridgeBio's $13.5B market cap.
  • Cross-filing context shows multiple amplifier signals for this cluster, including proximity to earnings, agreements, offerings, and press events.

Financial Impact

Total insider sales of $1.24M, or 0.009% of market cap.

insider_sales

Risk Factors

  • Insider sales may signal management's view that the stock is fully valued or that near-term catalysts are uncertain.
  • Cross-filing amplifier signals suggest potential upcoming corporate events (earnings, offerings, agreements) that could introduce volatility.
  • Historical calibration shows low win rates (22-32%) for similar impact scores in this segment, suggesting the market may not react strongly to this pattern.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
97% bullish (30 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-BBIO-1779828894709
26 reports for BBIO
Performance horizon
89% Hit rate 8 of 9 directional calls best @ T+60▲ +26.76%May 11, 2026
Filters
Rows
Reports for BBIO — sortable, filterable
TypeNow
Aug 31, 2026
4w ago
8-K
NEUTRAL ★ 4/10
$76.59 $65.97▼ −13.87%▼ −13.68%$67.47 (−11.90%)
Aug 26, 2026
5w ago
Press Release
BULLISH ★ 7/10
$79.37 $66.28▼ −16.49%▼ −16.72%$67.47 (−14.99%)
Aug 22, 2026
5w ago
Institutional Cluster
MIXED ★ 6/10
$81.07 $69.23▼ −14.60%▼ −15.92%$67.47 (−16.77%)
Aug 17, 2026
6w ago
8-K
NEUTRAL ★ 4/10
$79.89 $72.38▼ −9.40%▼ −7.87%$67.47 (−15.54%)
Aug 13, 2026
7w ago
Press Release
BEARISH ★ 5/10
$79.86 $72.38▲ +9.37%▲ +7.38%$67.47 (+15.51%)
Aug 10, 2026
7w ago
8-K
NEUTRAL ★ 5/10
$84.67 $76.08▼ −10.15%▼ −9.09%$67.47 (−20.31%)
Aug 10, 2026
7w ago
Press Release
MIXED ★ 6/10
$84.67 $76.08▼ −10.15%▼ −9.09%$67.47 (−20.31%)
Jul 13, 2026
11w ago
Insider Cluster
NEUTRAL ★ 3/10
$83.08 $84.67▲ +1.91%▼ −1.27%$67.47 (−18.78%)
Jun 28, 2026
13w ago
Press Release
BULLISH ★ 8/10
$72.01 $84.02▲ +16.68%▲ +16.96%$67.47 (−6.30%)
Jun 24, 2026
14w ago
144
NEUTRAL ★ 2/10
$69.69 $82.93▲ +19.00%▲ +18.47%$67.47 (−3.18%)
Showing 10 of 26

US Market Status

Market Open — Closes in 2h 18m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 26, 2026